From Local Champions to Global Competitors: An Interview with Dr. Magda Marquet and Dr. Francois Ferré, co-founders of Althea Technologies
San Diego-based biopharmaceuticals contract manufacturer Althea Technologies is officially part of Japanese conglomerate Ajinomoto Co., Inc. Ajinomoto paid approximately $175M for Althea Technologies. Althea has been renamed Ajinomoto Althea, Inc.
Althea was a provider of contract manufacturing services, and provided both clinical and commercial product development services.
Where are they today “Business as usual?”
o What are some of the challenges faced as entrepreneurs?
o What have been some of the challenges and benefits of globalization after the merger?
o How has the culture been impacted after the merger?
o Lessons learned….
Dr. Marquet is co-Founder and co-Chair of Ajinomoto Althea, Inc. and served as co-CEO from 1998-2008. She is also co-Founder and Director of Althea Dx, a spin-off of Althea Technologies, focusing in personalized medicine and companion diagnostics development. She has three decades of experience in the biotechnology industry in the United States and Europe.
About Francois :
Dr. François Ferré is the co-Chairman and co-Founder of AltheaDx, a privately-held company (spinoff of Althea Technologies) focusing in the development of companion diagnostics in oncology. Dr. Ferre was the CEO of AltheaDx from 2010 to June 2013. Prior to AltheaDx, Dr. Ferré co-founded Althea technologies and served as co-CEO from 1998 until 2008. He was a Director of Althea Technologiesuntil April 2013 and has recently been appointed a Director of Ajinomoto-Althea after the acquisition of the company by Ajinomoto.